TheTechno Optimist.

Eli Lilly—Eli Lilly acquires Orna Therapeutics for up to $2.4 billion to advance in vivo CAR-T cell therapiesEloralintideEli Lilly—Eli Lilly advances eloralintide (amylin agonist) to phase 3 trials for obesity as monotherapy and add-on to incretin drugsRetatrutideEli Lilly—Lilly to present TRIUMPH-2 at EASD 2026: retatrutide gave large weight loss and A1C cuts in obesity with type 2 diabetesTirzepatide (Mounjaro / Zepbound)Eli Lilly—FDA approves Mounjaro to reduce heart attack, stroke and cardiovascular death risk in adults with type 2 diabetesOrforglipron (Foundayo)Eli Lilly—Lilly to present ACHIEVE-4, its largest and longest Foundayo study in type 2 diabetes, at EASD 2026RetatrutideEli Lilly—Retatrutide TRIUMPH-1: 28.3% mean weight loss at 80 weeks on 12 mg vs 2.2% on placeboRetatrutideEli Lilly—Lilly sues six companies selling unauthorised retatrutide, which is not yet approvedVERVE-102 (PCSK9 base editor)Eli Lilly—NEJM publishes Heart-2 Phase 1 results: VERVE-102 lowered LDL by 62% on average at the top dose, lasting at least a yearOrforglipron (Foundayo)Eli Lilly—FDA approves Foundayo (orforglipron), an oral GLP-1 pill for obesity, under a national priority voucherEli Lilly—Eli Lilly's market capitalization passes $1 trillionOrforglipron (Foundayo)Eli Lilly—UK authorises orforglipron for weight management and type 2 diabetes

Eloralintide

by Eli LillyUS

A selective amylin receptor agonist for obesity treatment. Eli Lilly is evaluating it as a monotherapy and as a complementary treatment to incretin therapy for weight loss.

PilotStage 3 of 5

Phase 3 trials (ENLIGHTEN-1, ENLIGHTEN-6) enrolling in 2026, targeting 2028 completion.

Updated Feb 2026Checked 10 Oct0 updates this week

Milestones

Next · Phase 3 ENLIGHTEN-1 enrollment begins (monotherapy, obesity)
  1. Phase 2 trial achieves primary endpoint2025Complete.
  2. Phase 2 data presented at ObesityWeek2025Complete.
  3. Phase 3 ENLIGHTEN-1 enrollment begins (monotherapy, obesity)Target Feb 2026Current milestone.
  4. Phase 3 ENLIGHTEN-6 enrollment begins (add-on to incretin therapy)Feb 2026Complete.
  5. Phase 3 primary completionTarget Mar 2028Not yet reached.

Most important updates

Upcoming

  1. Feb 2026Phase 3 ENLIGHTEN-1 enrollment begins (monotherapy, obesity) (next)
  2. Mar 2028Phase 3 primary completion
Primer